You are here

SBIR TOPIC 97 - PHASE II - MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N92019C00002
Agency Tracking Number: N44HL190002
Amount: $727,427.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: N/A
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
5930 Star Ln. Suite C
Houston, TX 00007-7057
United States
DUNS: 828862701
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Alberto Gandini
 (412) 540-5227
 agandini@acceldx.com
Business Contact
 Alberto Gandini
Phone: (412) 540-5227
Email: agandini@acceldx.com
Research Institution
N/A
Abstract

Cardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government